KARAKTERISTIK PASIEN TUBERKULOSIS PARU DENGAN MULTIDRUG-RESISTANT (TB MDR) DI RSUD DR. M. HAULUSSY AMBON TAHUN 2014-2018
Abstract
Tuberculosis (TB) is an infectious disease caused by the bacterium Mycobacterium tuberculosis. The last few decades emerged another problem related to tuberculosis namely MDR TB (Tuberculosis with multidrug-resistant) which is very widespread. MDR TB treatment takes 2 years and with drugs that are 100 times more expensive when compared to first-line treatment. The purpose of this research was to determine the characteristics of multidrug-resistant pulmonary tuberculosis patients (MDR TB) in Dr. M. Haulussy Ambon in 2014 - 2018. This research is an observational descriptive research with cross sectional approach. The sampling technique is to use the total sampling method. The sample in this research amounted to 113 people. MDR TB patient medical record data obtained were then analyzed using Microsoft Excel. The results of the research showed that in RSUD Dr. M. Haulussy Ambon, MDR TB sufferers were mostly found in adulthood 26 - 45 years, namely 61 cases (54%), MDR TB patients were male, 69 cases (61%), type of patient relapsed 67 cases (59% ), 39 cases (34.51%) with duration of treatment 0 - 5, rifampicin-resistant patients were 79 cases (69.9%), patients died as many as 32 cases (28.3%) and there were 8 cases (7.1 %) MDR TB p atients are HIV positive.Downloads
References
Kementerian Kesehatan RI.Tuberculosis. Jakarta Selatan: Pusat data dan informasi; 2018.
World Health Organization. Global Tuberculosis Report. Jenewa; 2017.
World Health Organization. Global Tuberculosis Report. Jenewa; 2018.
Kementerian Kesehatan RI. Profil Kesehatan Indonesia Tahun 2018. Kementerian Kesehatan Republik Indonesia. 2019.
World Health Organization. Tuberculosis control in the South-East Asia region. Regional Office for South-East Asia; 2012.
Pusat data dan informasi. Tuberculosis. Jakarta Selatan: Kementrian Kesehatan RI; 2016.
Kementerian Kesehatan RI. Programmatic management of drug resistance tuberculosis. Jakarta: 2011.
Novizar D, Nawas A, Burhan E. Identifikasi faktor risiko tuberkulosis multidrug resistant.Majalah Kedokteran Indonesia.2010; 60 (12).
Yuni I.D.A.M.A. Hubungan fase pengobatan TB dan pengetahuan tentang MDR TB dengan kepatuhan pengobatan pasien TB(Studi di Puskesmas Perak Timur). Jurnal Berkala Epidemiologi. 2016;4(3):301–312.
Aini Z.M dan Rufia N.M. Karakteristik Penderita Tuberculosis Multidrug Resistant (TB MDR) diSulawesi Tenggara Tahun 2014-2017. Medula 6(2):547-557.
World Health Organization. Global Tuberculosis Control2012. Geneva. 2012.
Crofton J, Horne N dan Miller F.TuberkulosisKlinis. Jakarta: PT Widya Medika. 2002.
World Health Organization. Global Tuberculosis Report2015. Geneva. 2015.
Sihombing H, Sembiring H, Amir Z, Sinaga BYM. Pola resistensi primer pada penderita TB paru kategori I di RSUP H. Adam Malik, Medan. J Respir Indo. 2012;32(3): 1-8.
Nofizar D, Nawas A, Burhan E. Identifikasi Faktor risiko tuberkulosis multidrug resistant (TB-MDR). Majalah Kedokteran Indonesia. 2010; 60(12): 537-546.
Nakagawa MY, Ozasa K, Yamada N, et al. Gender difference in delays to diagnosis and health care seeking behaviour in a ruralarea of Nepal. INC J Tuber Lung Dis. 2001; 5(2): 24-31.
Nugroho F.S, Shaluhiyah Z dan Adi S. Gambaran Perilaku Pengobatan Pasien TB MDR Fase Intensif Di RS Dr Moewardi Surakarta. Jurnal Kesehatan. 2018;11(1):32-42.
Sarwani D.S.R, Nurlaela S dan Zahrotul I.A. Faktor Risiko Multidrug Resistant Tuberculosis (MDR-TB). Jurnal Kesehatan Masyarakat. 2012;8(1):60-66.
Rohmad. Faktor Risiko Terjadinya Relapse Pada Penderita Tuberkulosis Paru Di Balai Besar Kesehatan ParuMasyarakat (BBKPM) Surakarta. Skripsi. Program Studi Kesehatan Masyarakat. Fakultas Ilmu Kesehatan. Universitas Muhammadiyah Surakarta. 2012.
Karminiasih N.L.P, Putra I.W.G.A.E,Duarsa D.P,Rai I.B.N dan KarmayaI.N.MFaktorRisiko Kekambuhan Pasien TB Paru Di Kota Denpasar: Studi Kasus Kontrol. Public Health and Preventive Medicine Archive (PHPMA). 2016;4(1):17-22
WHO. Companion Handbook to The WHO Guidelines for The Programmatic Management Of Drug-Resistant Tuberculosis.Switzerland: WHO Press; 2014
Fatmawati U dan Kusmiati T. Characteristics and the Side Effects of New MDR-TB Treatmentin the Dr. Soetomo Hospital during 2016. Jurnal Respirasi. 2017;3(3):67-73.
Meyer K. Tuberculosis, Multi Drug Resistant. Dir Unit Tuberc OperPolicy Res Med Res Counc Pretoris. 2005;25(2).
WHO. Management of MDR TB; A Field Guides A Companion Document to Guidelines for Programmatic Management of Drug–Resitant Tuberculosis Integrated Management of Adolescent andAdult Illness (IMAI). Geneva; 2009.
Kementerian Kesehatan RI. Petunjuk Teknis Pengobatan Pasien Tb Resisten Obat Dengan Pedoman Panduan Standar Jangka Pendek di FASYANKES TB Resisten Obat. Jakarta. 2017.
Munir S.M, Nawas A dan Soetoyo D.K. Pengamatan pasien tuberculosis paru dengan multidrug-resistant (TB-MDR) di Poliklinik Paru RSUP Persahabatan. J Respir Indo. 2010;30(2): 92-105.
Anggia V.P, Indra P.Y dan Fauzia D. Profil Pasien Tuberculosis Multidrug Resistance (TB-MDR) di Poliklinik TB MDR RSUD Arifin Achmad Provinsi Riau Periode April 2013-Juni 2014. JOM FK. 2015;1(2).
Azwar G.A, Noviana D.I dan Hendriyono. F.X. Karakteristik Penderita Tuberkulosis Paru Dengan Multidrug-Resistant Tuberculosis (MDR-TB) di RSUD Ulin Banjarmasin. Berkala Kedokteran. 2017;13(1):23-32
Ayuningsih Z dan Wahyono T.Y.M. Faktor yang Berhubungan dengan Kematian Pasien TB MDR SelamaMasa Pengobatan di Indonesia Tahun 2015-2017. Pro Health Jurnal Ilmiah Kesehatan. 2019;1(2):41
Copyright (c) 2021 PAMERI: Pattimura Medical Review
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
